Eric Dinnerstein, MD
Neurology · Scarborough, MENPI 1740380153
Payments from drug & device makers
What this record shows
This record is dominated by education: $197 of the $197 with a category attached, or 100.0%. Eisai Inc. accounts for 70.5% of it on its own, with 2 other manufacturers making up the rest. 2023 is the largest year on record at $139, more than ten times the $7 reported in 2019. That places this record below the midpoint for neurology clinicians in ME, where the typical reported total is $180.
Across 9 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$139
- Biogen$41
- Travere Therapeutics, Inc.$17
Across 29 payments — averaging $21,535 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$569K
- Genentech, Inc.$56K
What the payments were for
- Education$197100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 2 | $139 |
| Biogen | 1 | $41 |
| Travere Therapeutics, Inc. | 6 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$134
How this compares
$197 in reported general payments places this provider in the 50th percentile of 69 neurology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 134 | $26,069 |
| Memantine Hcl | 508 | $25,521 |
| Tetrabenazine | 12 | $24,005 |
| Nurtec OdtRimegepant Sulfate | 11 | $12,382 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,910 |
| Memantine Hcl ErMemantine Hcl | 50 | $6,747 |
| Donepezil Hcl | 356 | $4,191 |
| Acetazolamide | 15 | $1,829 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 175 | $1,565 |
| RivastigmineRivastigmine Tartrate | 27 | $1,406 |
| Lacosamide | 13 | $1,255 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $893 |
| Levetiracetam | 16 | $406 |
| Sertraline Hcl | 34 | $374 |
| AmantadineAmantadine Hcl | 16 | $366 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scarborough
- Heidi HenningerScarborough$350K
- Helia MaghziScarborough$37K
- Edward DrasbyScarborough$22K
- Christine Lu-EmersonScarborough$4K
- Dustin SmythScarborough$1K
- Jacob StoutScarborough$685
- Paul MuscatScarborough$471
- Tamara SchwartzScarborough$231
- Diana GoodmanScarborough$180
- Will Valenti-MckeenScarborough$146
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.